Phase II study of OSI-774 in patients with metastatic colorectal cancer

被引：0
|
作者：
Townsley, C
Major, P
Siu, LL
Dancey, J
Vincent, M
Pond, G
MacLean, M
Moore, MJ
Oza, AM
机构：
[1] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada
[2] Hamilton Reg Canc Ctr, Dept Med Oncol, Hamilton, ON L8V 1C3, Canada
[3] Natl Canc Inst, Div Canc Treatment Diagnosis Ctr, Rockville, MD USA
[4] London Reg Canc Ctr, Dept Med Oncol, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
179
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
    C A Townsley
    P Major
    L L Siu
    J Dancey
    E Chen
    G R Pond
    T Nicklee
    J Ho
    D Hedley
    M Tsao
    M J Moore
    A M Oza
    British Journal of Cancer, 2006, 94 : 1136 - 1143
  • [2] Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
    Townsley, CA
    Major, P
    Siu, LL
    Dancey, J
    Chen, E
    Pond, GR
    Nicklee, T
    Ho, J
    Hedley, D
    Tsao, M
    Moore, MJ
    Oza, AM
    BRITISH JOURNAL OF CANCER, 2006, 94 (08) : 1136 - 1143
  • [3] Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer
    Philip, PA
    Mahoney, MR
    Allmer, C
    Thomas, J
    Pitot, HC
    Kim, G
    Donehower, RC
    Fitch, T
    Picus, J
    Erlichman, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6657 - 6663
  • [4] OSI-774 in advanced Esophageal Cancer: A phase II study.
    Radovich, D
    Kelsen, D
    Shah, M
    Klimstra, D
    Gavin, SG
    Munoz, D
    Ilson, DH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 332S - 332S
  • [5] Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J. F. de Groot
    M. R. Gilbert
    K. Aldape
    K. R. Hess
    T. A. Hanna
    S. Ictech
    M. D. Groves
    C. Conrad
    H. Colman
    V. K. Puduvalli
    V. Levin
    W. K. A. Yung
    Journal of Neuro-Oncology, 2008, 90 : 89 - 97
  • [6] Phase II trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer.
    Philip, PA
    Mahoney, M
    Thomas, J
    Pitot, H
    Donehower, R
    Kim, G
    Picus, J
    Fitch, T
    Geyer, S
    Erlichman, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 319S - 319S
  • [7] A phase II Study of OSI-774 in unresectable hepatocellular carcinoma.
    Thomas, MB
    Faria, S
    Tamm, E
    Rashid, A
    Charnsangavej, C
    Dancey, J
    Abbruzzese, J
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6092S - 6092S
  • [8] Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    de Groot, J. F.
    Gilbert, M. R.
    Aldape, K.
    Hess, K. R.
    Hanna, T. A.
    Ictech, S.
    Groves, M. D.
    Conrad, C.
    Colman, H.
    Puduvalli, V. K.
    Levin, V.
    Yung, W. K. A.
    JOURNAL OF NEURO-ONCOLOGY, 2008, 90 (01) : 89 - 97
  • [9] Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN).
    Rhoades, CA
    Kraut, E
    Schuller, D
    Zhang, Y
    Chan, K
    Lang, K
    Eng, C
    Grever, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 498S - 498S
  • [10] Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
    Rhoades, C
    Kraut, E
    Schuller, D
    Chan, K
    Lang, K
    Eng, C
    Grever, M
    Richard, J
    LUNG CANCER, 2004, 46 : S79 - S79
12345